Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients

[Background/Objectives]: Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many of them become platelet transfusion-dependent. Eltrombopag is...

Full description

Bibliographic Details
Authors: Mingot-Castellano, María Eva, Reguera-Ortega, Juan Luis, Zafra Torres, Denis, Hernani, Rafael, López-Godino, Oriana, Guerreiro, Manuel, Herrero, Blanca, López-Corral, Lucía, Luna, Alejandro, Gonzalez-Pinedo, Lesli, Chinea, Anabelle, Africa-Martín, Ana, Bailén, Rebeca, Martínez-Cibrián, Nuria, Balsalobre, Pascual, Filaferro, Silvia, Alonso-Saladrigues, Anna, Barba, Pere, Pérez-Martínez, Antonio, Pérez-Simón, José A., Sánchez-Pina, José María
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/382217
Online Access:http://hdl.handle.net/10261/382217
Access Level:Open access
Keyword:CAR-T
Thrombocytopenia
Platelet transfusion
Neutropenia
Red blood cell transfusion
Pan-cytopenia
Thrombopoietin receptor agonist
Eltrombopag
Adverse events
Description
Summary:[Background/Objectives]: Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many of them become platelet transfusion-dependent. Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) able to accelerate megakaryopoiesis, which has been used successfully in patients with bone marrow failure and immune thrombocytopenia (ITP). Its role in managing thrombocytopenia and other cytopenias in CAR-T cell-treated patients has been scarcely addressed. Our aim was to report the safety and efficacy of this approach in patients included in the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC) registry.

Similar Items